CD40 and primary progressive multiple sclerosis: Further, treated PPMS subjects in comparison with untreated PPMS subjects also had significantly decreased percentages of CD192 and CD40 in nonclassical monocytes (p < 0.05; and p < 0.01) (Figure 4).